Estimaciones de analistas de Wall Street para Ligand Pharmaceuticals Incorporated (LGND): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-05 | $2.30 | ||
| 2026-08-06 | $2.37 | $2.01 | +17.9% |
| 2026-05-14 | $1.63 | $1.84 | -11.4% |
| 2026-02-26 | $2.02 | $1.46 | +38.4% |
| 2025-11-06 | $3.09 | $1.97 | +56.9% |
| 2025-08-07 | $1.60 | $1.42 | +12.7% |
| 2025-05-08 | $1.33 | $1.21 | +9.9% |
| 2025-02-27 | $-1.64 | $1.37 | -219.7% |
Ratios de valoración
| Ratio P/E | 27.49 |
| Precio / Valor contable | 5.71 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $109.0M | $141.1M | $251.5M | $120.3M | $163.6M | $241.5M | $196.2M | $131.3M | $167.1M | $268.1M |
| Coste de Ventas | $5.6M | $5.4M | $6.3M | $11.3M | $30.4M | $62.2M | $52.8M | $35.0M | $11.1M | $6.6M |
| Beneficio Bruto | $103.4M | $135.7M | $245.1M | $108.9M | $133.1M | $179.4M | $143.4M | $96.3M | $156.1M | $261.5M |
| I+D | $21.2M | $26.9M | $27.9M | $55.9M | $40.5M | $32.1M | $36.1M | $24.5M | $21.4M | $81.2M |
| Generales y Administrativos | $26.6M | $28.7M | $37.7M | $41.9M | $60.0M | $46.8M | $70.1M | $52.8M | $78.7M | $92.4M |
| Gastos Operativos | $58.5M | $67.7M | $81.4M | -$698.1M | $95.6M | $75.5M | $140.4M | $84.3M | $178.7M | $214.3M |
| Beneficio Operativo | $43.9M | $68.1M | $163.7M | $807.1M | $37.5M | $103.9M | $3.0M | $11.9M | -$22.6M | $47.2M |
| EBITDA | $55.2M | $81.2M | $238.3M | $876.1M | $56.7M | $142.8M | $81.2M | $100.8M | $40.8M | $192.7M |
| Gastos por Intereses | $12.2M | $11.4M | $48.3M | $35.7M | $27.4M | $19.6M | $1.8M | $656000 | $3.0M | $4.7M |
| Beneficio Antes de Impuestos | $8.0M | $57.2M | $173.3M | $796.6M | $1.3M | $72.2M | $36.0M | $63.7M | $2.5M | $159.0M |
| Impuestos | $10.3M | $44.7M | $30.0M | $167.3M | -$5.3M | -$4.1M | $41.2M | $9.8M | $6.5M | $34.5M |
| Beneficio Neto | -$1.6M | $12.6M | $143.3M | $629.3M | -$3.0M | $57.1M | -$33.4M | $52.2M | -$4.0M | $124.5M |
| BPA | $-0.08 | $0.60 | $5.96 | $33.13 | $-0.18 | $3.46 | $-1.98 | $3.02 | $-0.22 | $6.44 |
| BPA Diluido | $-0.08 | $0.53 | $5.96 | $31.85 | $-0.18 | $3.34 | $-1.98 | $2.94 | $-0.22 | $6.13 |
| Acciones en Circulación (Diluidas) | $20.8M | $23.5M | $24.1M | $19.8M | $16.2M | $17.2M | $16.9M | $17.8M | $18.3M | $20.3M |
Precio
| Precio | $275.20 |
| Capitalización | $5.5B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ACAD · ADMA · BLTE · CRNX · DYN · MIRM · NAMS
Explorar sector: Healthcare · Biotechnology
Más secciones de LGND: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones